Education
About Us
Working with TipRanks
Follow Us
Summit Therapeutics (SMMT)
NASDAQ:SMMT
SMMT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.10 - $33.89
Previous CloseN/A
Volume1.23M
Average Volume (3M)2.66M
Market Cap
$13.95B
Enterprise Value$12.76B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.42
Next Earnings
May 08, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding737,679,700
10 Day Avg. Volume2,381,827
30 Day Avg. Volume2,656,599
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-74.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-849.95
Enterprise Value/Ebitda-59.99
Forecast
1Y Price Target
$35.50Price Target Upside104.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessIvonescimab shows lower high-grade treatment-related adverse events compared to BNT327, suggesting a better safety profile.
Earnings PotentialSummit Therapeutics holds a meaningful two-year first-to-market advantage over several competitors in the clinical development phase.
Market PotentialIvonescimab is seen as the heir apparent to Keytruda, considered the biggest cancer drug in history.
Bears Say
Clinical Trial ConcernsInvestors will face an inconvenient data point with the expectation that HARMONi will not achieve significance on overall survival in the 2L EGFRm Ph3 trial.
Market ChallengesSummit Therapeutics does not currently have active trials in extensive-stage small cell lung cancer.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SMMT FAQ
What was Summit Therapeutics’s price range in the past 12 months?
Summit Therapeutics lowest stock price was $2.10 and its highest was $33.89 in the past 12 months.
What is Summit Therapeutics’s market cap?
Summit Therapeutics’s market cap is $13.95B.
When is Summit Therapeutics’s upcoming earnings report date?
Summit Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 33 days.
How were Summit Therapeutics’s earnings last quarter?
Summit Therapeutics released its earnings results on Feb 24, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.082 by $0.002.
Is Summit Therapeutics overvalued?
According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued.
Does Summit Therapeutics pay dividends?
Summit Therapeutics does not currently pay dividends.
What is Summit Therapeutics’s EPS estimate?
Summit Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Summit Therapeutics have?
Summit Therapeutics has 737,679,700 shares outstanding.
What happened to Summit Therapeutics’s price movement after its last earnings report?
Summit Therapeutics reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.082. Following the earnings report the stock price went down -14.828%.
Which hedge fund is a major shareholder of Summit Therapeutics?
Currently, no hedge funds are holding shares in SMMT
---
Summit Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.50 (104.49% Upside)
$35.50 (104.49% Upside)
Blogger Sentiment
Bullish
SMMT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 11.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
390.39%
12-Months-Change
Fundamentals
Return on Equity
-94.89%
Trailing 12-Months
Asset Growth
114.62%
Trailing 12-Months
Company Description
Summit Therapeutics
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
---
SMMT Company Deck
---
SMMT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Summit Therapeutics, marked by significant collaborations, financial stability, and progress in clinical trials. However, some uncertainties around trial timelines and reliance on partnerships were noted.Read More>---
SMMT Stock 12 Month Forecast
Average Price Target
$35.50
▲(104.49% Upside)
Technical Analysis
Best Analysts Covering SMMT
1 Year
1 Year Success Rate
4/5 ratings generated profit
1 Year Average Return
+112.72%
upgraded a buy rating 11 days ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +112.72% per trade.
---